JP2020511494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511494A5 JP2020511494A5 JP2019551608A JP2019551608A JP2020511494A5 JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5 JP 2019551608 A JP2019551608 A JP 2019551608A JP 2019551608 A JP2019551608 A JP 2019551608A JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- composition
- natriuretic peptide
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022070710A JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| US62/475,147 | 2017-03-22 | ||
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Division JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511494A JP2020511494A (ja) | 2020-04-16 |
| JP2020511494A5 true JP2020511494A5 (https=) | 2021-04-01 |
| JP7126270B2 JP7126270B2 (ja) | 2022-08-26 |
Family
ID=63585777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551608A Active JP7126270B2 (ja) | 2017-03-22 | 2018-03-21 | Ｎｐｒａアゴニスト、組成物およびその使用 |
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (https=) |
| EP (1) | EP3601314A4 (https=) |
| JP (2) | JP7126270B2 (https=) |
| KR (1) | KR102714599B1 (https=) |
| CN (1) | CN110603260B (https=) |
| AU (2) | AU2018239352A1 (https=) |
| BR (1) | BR112019019720A2 (https=) |
| CA (1) | CA3056433A1 (https=) |
| EA (1) | EA201992226A1 (https=) |
| IL (1) | IL269388B2 (https=) |
| MX (1) | MX2019010960A (https=) |
| MY (1) | MY201165A (https=) |
| PH (1) | PH12019550163A1 (https=) |
| SG (1) | SG11201908580XA (https=) |
| WO (1) | WO2018175534A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12440496B2 (en) | 2019-05-22 | 2025-10-14 | Merck Sharp & Dohme Llc | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20220281886A1 (en) * | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| JP2023530273A (ja) * | 2020-06-12 | 2023-07-14 | ファーマイン コーポレイション | Ｃ型ナトリウム利尿ペプチド及び癌の処置におけるその方法 |
| CN115803338A (zh) * | 2020-06-12 | 2023-03-14 | 药明公司 | C型利尿钠肽及其治疗急性肺损伤的方法 |
| WO2024086680A2 (en) | 2022-10-21 | 2024-04-25 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| WO2004047871A2 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| KR101350251B1 (ko) * | 2008-05-23 | 2014-01-14 | 다이이찌 산쿄 가부시키가이샤 | 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드 |
| PT2432489T (pt) * | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
| EP2678028A2 (en) * | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 KR KR1020197031122A patent/KR102714599B1/ko active Active
- 2018-03-21 MY MYPI2019005393A patent/MY201165A/en unknown
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en not_active Ceased
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en not_active Abandoned
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 IL IL269388A patent/IL269388B2/en unknown
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201270A patent/AU2025201270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511494A5 (https=) | ||
| US8603969B2 (en) | Pancreatic polypeptide family motifs and polypeptides comprising the same | |
| JP4173914B2 (ja) | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 | |
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2017518303A5 (https=) | ||
| JP2014521684A5 (https=) | ||
| MX2014012625A (es) | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. | |
| AU2020200934B2 (en) | Long-acting adrenomedullin derivative | |
| JP7126270B2 (ja) | Ｎｐｒａアゴニスト、組成物およびその使用 | |
| KR20110095266A (ko) | 신장 장애 치료용 조성물 및 방법 | |
| JP7672677B2 (ja) | 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法 | |
| JP5687266B2 (ja) | 大動脈線維症の治療のための組成物および方法 | |
| CN108472333B (zh) | 组合 | |
| WO2016144968A1 (en) | Relaxin therapy for disorders of the diaphragm | |
| HK40088755A (zh) | Hbv和hdv感染的联合治疗 | |
| Javaheri et al. | Apolipoprotein M improves survival in congestive heart failure via enhanced Akt signaling | |
| McCarthy et al. | Acute and Chronic Vascular and Cardiac Effects of Serelaxin in the Angiotensin II/L-NAME Heart Failure Model | |
| Morine et al. | Neutralizing Endoglin Activity Rescues Maladaptive Remodeling in Heart Failure | |
| WO2009080608A1 (en) | Y2 receptor agonists | |
| Chen et al. | BUNP: A Novel Designer pGC-A/cGMP Activator with Enhanced Potency and High Selectivity In Vitro | |
| La Villa et al. | Effects of atrial (ANP) and C-type (CNP) natriuretic peptide on the renal release of endothelin-1 (ET-1) in man | |
| JP2020503356A5 (https=) |